MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
Abstract Background Frequent failure and severe side effects of current sarcoma therapy warrants new therapeutic approaches.The small-molecule MDM2 antagonist Nutlin-3a activates the p53 pathway and efficiently induces apoptosis in tumours with amplified MDM2 gene and overexpression of MDM2 protein.However, the majority of human sarcomas have norma